Mon panier

VCAM-1

VCAM-1 Informations sur la molécule

Nom anglaisVascular cell adhesion molecule 1Nombre de médicaments commercialisés2
Nombre de médicaments cliniques1Alias de la cibleVCAM1,Vascular cell adhesion protein 1,V-CAM 1,CD106,Vascular Cell Adhesion Molecule 1,CD106 Antigen,INCAM-100,VCAM-1,Vascular Cell Adhesion Molecule-1
Phase de R&D la plus avancéeApproved
Nom anglaisVascular cell adhesion molecule 1
Alias de la cibleVCAM1,Vascular cell adhesion protein 1,V-CAM 1,CD106,Vascular Cell Adhesion Molecule 1,CD106 Antigen,INCAM-100,VCAM-1,Vascular Cell Adhesion Molecule-1
Nombre de médicaments commercialisés2
Nombre de médicaments cliniques1
Phase de R&D la plus avancéeApproved

VCAM-1Contexte de la molécule

Vascular cell adhesion protein 1 (VCAM1) is also known as CD106, INCAM-100 and L1CAM, is a cell surface sialoglycoprotein belonging to the immunoglobulin superfamily. VCAM1 / CD106 contains 7 Ig-like C2-type (immunoglobulin-like) domains. CD106 / VCAM-1 is expressed on inflammed vascular endothelium, as well as on macrophage-like and dendritic cell types in both normal and inflammed tissue. L1CAM / VCAM-1 is Important in cell-cell recognition and appears to function in leukocyte-endothelial cell adhesion. CD106 / VCAM1 interacts with the beta-1 integrin VLA4 on leukocytes, and mediates both adhesion and signal transduction. The VCAM1 / VLA4 interaction may play a pathophysiologic role both in immune responses and in leukocyte emigration to sites of inflammation. INCAM-100 / VCAM1 binds to ECMV-D capsid proteins and acts as a receptor for this virus.

VCAM-1Alias de la molécule

VCAM1,CD106,INCAM-100,V-CAM 1,VCAM-1

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
99mTc-cAbVCAM1-599mTccAbVCAM1‐5; 99mTc-cAbVCAM1-5Phase 1 ClinicalMedico-Economic Evaluation Unit , University Hospital, GrenobleAtherosclerosis; Cardiovascular Diseases
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
Tocopherol acetateDSE-9912ApprovedNational Institute Of Diabetes And Digestive And Kidney DiseasesEphynal, Aquasol EJapanVitamin E Deficiency; Diabetic Retinopathy; Atherosclerosis; Intermittent Claudication; Venous Thromboembolism; ThrombosisEisai Co Ltd1951-09-01Atherosclerosis; Diabetic Retinopathy; Intermittent Claudication; Metabolic Dysfunction-Associated Steatotic Liver Disease; Thrombosis; Venous Thromboembolism; Vitamin E Deficiency
Details
Ascorbic Acid/Biotin/Cholecalciferol/Cyanocobalamin/Dexpanthenol/Folic acid/Niacinamide/Pyridoxine/Riboflavin/Thiamine/Tocopherol Acetate/Vitamin A/Vitamin KApprovedSandoz Canada IncInfuvite PediatricUnited StatesAvitaminosisSandoz Canada Inc2001-02-21Avitaminosis
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments commercialisés
  • Informations sur les médicaments cliniques